VulVaccin study
Phase 1
- Conditions
- Vulvar High-Grade Squamous Intraepithelial Lesion (vHSIL)Therapeutic area: Diseases [C] - Virus Diseases [C02]Therapeutic area: Diseases [C] - Female Urogenital Diseases and Pregnancy Complications [C13]
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- Not specified
- Target Recruitment
- 498
Inclusion Criteria
Women 18 years or older, Vulvar High-grade Squamous Intraepithelial Lesion (HSIL), histologically proven, Planned for treatment (surgical, laser or imiquimod) for vulvar High Grade Squamous Intraepithelial Lesion
Exclusion Criteria
Prior HPV vaccination, (Micro-) invasive carcinoma or history of HPV related genital carcinoma (cervix, anal, vulva), Pregnancy, Women allergic to vaccine components, HIV infection, Immune compromised patients (currently on immunosuppressive medication)
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method